1. Home
  2. JOF vs LCTX Comparison

JOF vs LCTX Comparison

Compare JOF & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Japan Smaller Capitalization Fund Inc

JOF

Japan Smaller Capitalization Fund Inc

HOLD

Current Price

$12.63

Market Cap

328.1M

Sector

Finance

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.11

Market Cap

301.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JOF
LCTX
Founded
1990
1990
Country
Japan
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
328.1M
301.7M
IPO Year
1996
1996

Fundamental Metrics

Financial Performance
Metric
JOF
LCTX
Price
$12.63
$1.11
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$6.25
AVG Volume (30 Days)
70.7K
839.2K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
3.33%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,556,000.00
Revenue This Year
N/A
$109.40
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
53.24
52 Week Low
$9.95
$1.00
52 Week High
$12.76
$2.09

Technical Indicators

Market Signals
Indicator
JOF
LCTX
Relative Strength Index (RSI) 64.89 53.23
Support Level $12.13 $1.02
Resistance Level $12.72 $1.18
Average True Range (ATR) 0.14 0.05
MACD 0.00 0.01
Stochastic Oscillator 90.09 68.62

Price Performance

Historical Comparison
JOF
LCTX

About JOF Japan Smaller Capitalization Fund Inc

Japan Smaller Capitalization Fund Inc is a closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investments in smaller capitalization Japanese equity securities. Its portfolio of investments consists of different sectors such as banks, chemicals, construction, electric appliances, financing business, food, Information and Communication, Utilities, Real Estate, and others.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: